Affimed NV
AFMD0.130USD
-0.004-2.99%
Close 05/14, 16:00（ET）Quotes delayed by 15 min
2.13MMarket Cap
LossP/E TTM
More Details of Affimed NV Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Info
Company codeAFMD
Company nameAffimed NV
IPO dateSep 12, 2014
Founded at2014
CEOMr. Shawn M. Leland
Number of employees76
Security typeOrdinary Share
Fiscal year-endSep 12
AddressIm Neuenheimer Feld 582
CityHEIDELBERG
Stock exchangeNASDAQ Global Market Consolidated
CountryGermany
Postal code69120
Phone49621560030
Websitehttps://www.affimed.com/
Company codeAFMD
IPO dateSep 12, 2014
Founded at2014
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Revenue Breakdown
Currency: EURUpdate time: Sun, Apr 6
Currency: EURUpdate time: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
By RegionEUR
Name
Revenue
Proportion
United States
155.00K
100.00%
Germany
0.00
0.00%
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Shareholder
Update time: 23 hours ago
Update time: 23 hours ago
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Shareholder Statistics
Shareholder
Proportion
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Type
Shareholder
Proportion
Hedge Fund
8.99%
Venture Capital
8.49%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
2.72%
Investment Advisor
1.62%
Research Firm
0.83%
Other
71.34%
Institutional Shareholding
Update time: Sat, Feb 22
Update time: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
194
4.37M
28.73%
-2.85M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
2022Q4
311
9.75M
66.09%
-701.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
-270.00K
-29.20%
Dec 31, 2024
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Dec 31, 2024
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Dec 31, 2024
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Dec 31, 2024
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Dec 31, 2024
Intellectus Partners, LLC
126.41K
0.83%
+32.05K
+33.97%
Dec 31, 2024
Citadel Advisors LLC
114.77K
0.75%
+107.96K
+1.58K%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Date
Type
Ratio
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1